[1] Obesity:a growing threat to health in China. Lancet,2014,384:716. [2] Yeh MM,Brunt EM. Pathological features of fatty liver disease. Gastroenterology,2014,147:754-764. [3] Musso G,Gambino R,Cassader M,et al. Meta-analysis:natural history of non-alcoholic fatty liver disease(NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med,2011,43:617-649. [4] Joka D,Wahl K,Moeller S,et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology,2012,55:455-464. [5] 钱建成,陆璐,娄国强,等. 血清细胞角蛋白18诊断非酒精性脂肪性肝病的价值探讨. 实用肝脏病杂志,2012,15(4):291-294. [6] Chan WK,Sthaneshwar P,Nik Mustapha NR,et al. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis a comparison with routine biochemical markers. PLoS One,2014,9:e105903. [7] Chen J,Zhu Y,Zheng Q,et al. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis:A meta-analysis. Hepatol Res,2014,44:854-862. [8] Otgonsuren M,Estep MJ,Hossain N,et al. A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis(NASH). J Gastroenterol Hepatol,2014,Jul 6. doi:10.1111/jgh.12665.[Epub ahead of print]. [9] Bastati N,Feier D,Wibmer A,et al. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease:a proof-of-concept study. Radiology,2014,271:739-747. [10] Issa L,Goh GB,Lopez R,et al. The development of a non-invasive model to predict the presence of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology,2014,57 (Suppl 1):883A. [11] Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association,American Association for the Study of Liver Diseases,and American College of Gastroenterology. Gastroenterology,2012,142:1592-1609. [12] Musso G,Cassader M,Rosina F,et al. Impact of current treatments on liver disease,glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease(NAFLD):a systematic review and meta-analysis of randomised trials. Diabetologia,2012,55:885-904. |